News Breaks |
|
|
| January 7, 2013 |
| 09:55 EDT |  | INFI, INFI, SFE, SFE, CELG, CELG, IMGN, IMGN, NVS, NVS, QSII, QSII, THOR, THOR | JPMorgan to host a conference
31st Annual Global Healthcare Conference is being held in San Francisco on January 7-10 with webcasted company presentations to begin on January 7 at 10 am; not all company presentations may be webcasted. Webcast Link |
|
|
News For INFI;SFE;CELG;IMGN;NVS;QSII;THOR From The Last 14 Days Check below for free stories on INFI;SFE;CELG;IMGN;NVS;QSII;THOR the last two weeks. |
|
|
| June 19, 2013 |
| 07:57 EDT | | THOR, QSII | Wells Faro to host a conference
 Subscribe for More Information |
|
| June 18, 2013 |
| 11:20 EDT |  | INFI | Infinity Pharmaceuticals shares up 11%, or $1.97, to $19.14
Subscribe for More Information |
|
| 07:22 EDT | | NVS | Citigroup to host a conference
Subscribe for More Information |
|
| June 17, 2013 |
| 07:28 EDT | | NVS | Cambridge Healthtech Institute to host a conference
Subscribe for More Information |
|
| 07:25 EDT | | NVS | Leerink to host a conference
Subscribe for More Information |
|
| 05:44 EDT | | CELG | Celgene awarded marketing authorisation for Revlimid from EC
Subscribe for More Information |
|
| June 16, 2013 |
| 14:09 EDT | | NVS | Jakafi improved overall survival in Phase III trial of patients with myelofibros
Incyte (INCY) announced results from two ongoing clinical trials of Jakafi, ruxolitinib, an oral JAK1 and JAK2 inhibitor that is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis, MF, that were presented at the 18th Congress of the European Hematology Associationm EHA, in Stockholm, Sweden. In a three-year follow-up analysis of the Phase III COMFORT-II study, treatment with Jakafi, which is marketed as Jakavi by Novartis (NVS) outside the United States, was associated with improved overall survival and sustained reductions in spleen size compared to best available therapy. In a separate exploratory analysis of bone marrow fibrosis data from an ongoing Phase I/II single-arm, open-label clinical trial, by 48 months of treatment, Jakafi stabilized or reversed fibrosis of the bone marrow in 56 percent and 22 percent, respectively, of patients with MF, a magnitude of an effect not seen historically with best available therapy. |
|
| June 14, 2013 |
| 08:23 EDT |  | CELG | Celgene multiple likely to expand further, says Cantor
Cantor believes that Celgene is in the process of diversifying its revenue as it introduces new products. The firm has an upbeat outlook on the company's Apremilast drug and keeps a Buy rating on the stock. |
|
| 06:07 EDT | | CELG | Celgene achieves statistical significance for endpoints in Behcet trial
Subscribe for More Information |
|
| June 13, 2013 |
| 10:15 EDT | | CELG | Celgene management to meet with Jefferies
Subscribe for More Information |
| |
| 10:14 EDT | | CELG | Celgene management to meet with Guggenheim
Subscribe for More Information |
|
| 10:05 EDT |  | CELG | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:03 EDT | | CELG | Celgene should continue to be bought, says RW Baird
Baird continues to be buyers of Celgene citing its new $3B share repurchase program and the publication of new trial data for apremilast's PALACE-1 efficacy. Shares are Outperform rated with a $130 price target. |
|
| 07:33 EDT | | CELG | Celgene upgraded to Buy from Hold at Argus
Subscribe for More Information |
|
| 05:24 EDT | | CELG | Celgene presents data from PALACE 3 study
Celgene International Sàrl, a wholly-owned subsidiary of Celgene, announced results from PALACE 3, the company’s third phase III study in psoriatic arthritis, or PsA, at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain. The PALACE 3 study, which evaluated 495 patients, demonstrated statistical significance in achieving the primary endpoint of American College of Rheumatology 20 score at week 16 for patients receiving apremilast compared to placebo. PALACE 3 is the third pivotal phase III, randomized, placebo-controlled study evaluating Celgene’s novel, oral small-molecule inhibitor of phophodiesterase 4 in patients with active psoriatic arthritis who had previously received and/or failed an oral disease-modifying anti-rheumatic drug, or DMARD, and/or biologic therapy. In this study, apremilast treatment was used alone or in combination with oral DMARDs. By design, PALACE 3 includes a subset of 270 patients with significant active psoriatic skin involvement. Patients in the 30 mg BID active treatment arm also demonstrated significant and sustained improvements in psoriasis-related endpoints, including Psoriasis Area Severity Index, or PASI, 50 and PASI-75 at week 24. Similar improvements in 30 mg BID-treated patients were also observed in key secondary endpoints, including various measures of physical function, signs and symptoms and quality of life. The safety and tolerability profile of apremilast in PALACE 3 was consistent with other previously reported phase III studies of the therapy in psoriatic arthritis. |
|
| June 12, 2013 |
| 10:14 EDT |  | QSII | On the Fly: Initiation Summary
AMRI (AMRI) coverage resumed with a Buy at Sterne Agee… AMRI (AMRI) re-initiated with a Buy at Sterne Agee… Allscripts (MDRX) re-initiated with a Buy at Sterne Agee… Amkor Technology (AMKR) initiated with a Buy at Sidoti… Astec (ASTE) initiated with a Hold at Stifel… Bob Evans (BOBE) initiated with an Outperform at Oppenheimer… Calumet Specialty Products (CLMT) initiated with an Outperform at Credit Suisse… Cerner (CERN) re-initiated with a Neutral at Sterne Agee… Charles River Labs (CRL) re-initiated with a Buy at Sterne Agee… Covance (CVD) re-initiated with a Buy at Sterne Agee… First Republic Bank (FRC) initiated with an Overweight at Barclays… Greenway Medical (GWAY) re-initiated with an Underperform at Sterne Agee… Gulfport Energy (GPOR) re-initiated with an Outperform at Credit Suisse… ICON plc (ICLR) re-initiated with a Neutral at Sterne Agee… Manitowoc (MTW) initiated with a Buy at Stifel… PAREXEL (PRXL) re-initiated with a Neutral at Sterne Agee… Pacific Drilling (PACD) initiated with an Outperform at Credit Suisse… Perrigo (PRGO) initiated with an Overweight at Morgan Stanley… Quality Systems (QSII) re-initiated with a Neutral at Sterne Agee… Quintiles (Q) initiated with an Underperform at Sterne Agee… Reliance Steel (RS) initiated with a Hold at Topeka… SVB Financial (SIVB) initiated with an Equal Weight at Barclays… Terex (TEX) initiated with a Buy at Stifel… Texas Roadhouse (TXRH) initiated with a Buy at BofA/Merrill… Whiting Petroleum (WLL) initiated with an In-Line at Imperial Capital… athenahealth (ATHN) re-initiated with a Neutral at Sterne Agee. |
|
| 10:14 EDT | | THOR | On the Fly: Upgrade Summary
Subscribe for More Information |
|
| 08:01 EDT | | CELG | Celgene announces additional $3B share repurchase program
Celgene announced that its Board of Directors authorized the repurchase of up to an additional $3.0B of the company’s common stock. Year-to-date, Celgene has repurchased approximately $1.8B of its common stock and has exhausted the previous $2.5B stock repurchase authorization. |
|
| 08:00 EDT | | CELG | Celgene announces additional $3B share repurchase program
Subscribe for More Information |
|
| 07:38 EDT | | CELG | Celgene reports positive Phase III results from psoriatic arhrititis candidate
Subscribe for More Information |
| |
|
|
|
|
